# Open Label Study of Long Term Safety Evaluation of Alirocumab

Study · id `cardio:ct-nct01954394` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01954394](<https://clinicaltrials.gov/study/NCT01954394>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01954394

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 986 participants.

## Technical summary

Registry record NCT01954394. Allocation not applicable; no masking; primary purpose treatment. Start 2013-12-17 (registry gives no type); primary completion 2017-06-30 (actual). Results posted on 2018-07-24.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 986 participants (enrolled count; ClinicalTrials.gov record NCT01954394, source copy `cardio:ctgov-nct01954394-2018-07-24`, retrieved 2026-10-31)
- Start date: 2013-12-17 (registry gives no type) (ClinicalTrials.gov record NCT01954394, source copy `cardio:ctgov-nct01954394-2018-07-24`, retrieved 2026-10-31)
- Primary completion: 2017-06-30 (actual) (ClinicalTrials.gov record NCT01954394, source copy `cardio:ctgov-nct01954394-2018-07-24`, retrieved 2026-10-31)
- Completion: 2017-06-30 (actual) (ClinicalTrials.gov record NCT01954394, source copy `cardio:ctgov-nct01954394-2018-07-24`, retrieved 2026-10-31)
- Results first posted: 2018-07-24 (ClinicalTrials.gov record NCT01954394, source copy `cardio:ctgov-nct01954394-2018-07-24`, retrieved 2026-10-31)
- Countries: United States; Argentina; Austria; Belgium; Bulgaria; Canada; Czechia; Denmark; Finland; France; Germany; Hungary; Israel; Italy; Mexico; Netherlands; Norway; Portugal; Romania; Russia; South Africa; Spain; Sweden; United Kingdom (ClinicalTrials.gov record NCT01954394, source copy `cardio:ctgov-nct01954394-2018-07-24`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01954394-2018-07-24`, retrieved 2026-10-31)

## The registry's words

- Brief title: Open Label Study of Long Term Safety Evaluation of Alirocumab
- Acronym: ODYSSEY OLE
- Condition: Hypercholesterolemia
- Intervention (Drug): Alirocumab
- Intervention (Drug): Lipid-Modifying Therapy (LMT)
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY
- Collaborator: Regeneron Pharmaceuticals
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry intervention name matches this record: Alirocumab (`cardio:alirocumab`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)
- Registry lists this organization as a collaborator: Regeneron Pharmaceuticals (`cardio:org-regeneron-pharmaceuticals`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Alirocumab dosing patterns during 40 months of open-label treatment in patients with heterozygous familial hypercholesterolemia (`cardio:pubmed-30287210`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program (`cardio:pubmed-30293878`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 80723e09063fd1874a71a71b0d11caace88446c2d36fe6f6f01caf752d204388
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
